SOME patients taking part in phase 1 trials of Solbec Pharmaceuticals anti-cancer drug SBP002 have asked to continue taking the drug.
Solbec has announced that the drug had proved successful in reducing tumor sizes in some of the patients in the phase 1 trial.
The trial, which was designed to determine safe doses for the drug, will allow the company to move to phase 2 trials. There are 13 patients already enrolled for that stage.
Principle investigator in the Solbec trial Michael Millward said a number of patients had shown a positive response to the drug.
